CRI to give the 2022 William B . Coley Award for Distinguished Research in Basic and Tumor Immunology to celebrate molecular and mechanistic studies on gasdermins that revealed their critical role in a highly immunogenic form of cell death called pyroptosis, with preclinical studies showing significant promise to help more cancer patients respond to immunotherapy.
The free online event will connect cancer patients and caregivers with the latest promising research findings shared by top immunotherapy experts, patient success stories, and clinical trial updates, on September 22, 2022, at 2 p.m. ET
Six U.S. scientists have been awarded $1.25 million each over 5 years to conduct high-risk, high-reward cancer immunology research with potential to transform cancer treatment
Latest analysis from the Cancer Research Institute of the global landscape of cellular immunotherapies, including R&D trends and real-world usage, highlights key challenges including effective solid tumor targeting, manufacturing complexities, and commercial access to approved therapies
Awareness and educational program offerings for cancer patients and caregivers about the latest advances in cancer immunotherapy shared over 30 days in June
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).
Drs. Stefani Spranger and Elsa Anagnostou recap highlights relating to myeloid cells, tumor heterogeneity, and preclinical models from Day 2 of of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).